“State of Lung Cancer” Report Shows Need for Increased Screening Leading to Early Detection
“The American Lung Association’s 2024 “State of Lung Cancer” report ranks Florida 17 out of 47 surveyed states for survival of lung cancer at 29.1%. The report also shows a 25.3% early diagnoses rate in the state. Specialists at Moffitt Cancer Center continue to emphasize the importance of screening for those at risk. “Despite the remarkable advances we have made in treating advanced-stage lung cancer with immunotherapy, targeted agents, tumor-infiltrating lymphocyte therapy and other innovative approaches, the most effective way of significantly increasing the cure rate of lung cancer is finding it early, when it is confined to the lung and potentially curable,” Lary Robinson, MD, director of Moffitt’s Lung Cancer Early Detection Center said.
New Report Reveals South Dakota Among Best in Nation for Early Diagnosed Lung Cancer Cases American Lung Association’s ‘State of Lung Cancer’ report examines lung cancer in South Dakota
“SIOUX FALLS – The American Lung Association released its 2024 “State of Lung Cancer” report, which examines key indicators to highlight how the toll of lung cancer varies by state. Lung cancer is the leading cause of cancer deaths in South Dakota and across the U.S., but the report reveals positive news. The report finds South Dakota is ranked 10th in the nation for cases of lung cancer diagnosed at an early stage.”
Obesity-Specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin
“Conclusions: Metformin may improve lung cancer-specific clinical outcomes in obese and overweight lung cancer patients and enhance immunotherapy efficacy in this growing population as well. This work identifies obesity as a potential predictive biomarker of metformin’s anticancer and immunotherapy-enhancing properties in lung cancer while shedding light on the underlying immunological phenomena.”
New Research Sheds Light on a Surprising Connection Between COVID-19 and Cancer Regression
“A new Northwestern Medicine study published in The Journal of Clinical Investigation has revealed a connection between COVID-19 infection and cancer regression. The team’s discovery could pave the way for novel cancer treatments.”
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations
“Key Takeaways: FoundationOne Liquid CDx is approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib treatment. The VISION trial demonstrated tepotinib’s efficacy, with notable overall response rates and progression-free survival in mNSCLC patients.”
State of Lung Cancer
“States must do more to protect their residents from lung cancer.”
‘Troubling’ data show lack of awareness about lung cancer screening
“Key takeaways: Over 80% of people at high risk for lung cancer were unaware of screening or had not discussed it with a doctor. Informational interventions in clinics and communities could improve screening awareness.”
AstraZeneca and Daiichi Sankyo submit BLA to FDA for lung cancer treatment “AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) to the US Food and Drug Administration (FDA) seeking accelerated approval for datopotamab deruxtecan (Dato-DXd) to treat non-small cell lung cancer (NSCLC).”
